Evicenter
MarkdownMedical informationP&T meetings
VK2735

Chronic weight management

Last updated
184 sources

Executive summary

Conclusions

1 evidence topic · 15 sources

Summary

VK2735 is an investigational dual GLP-1 and GIP receptor agonist developed by Viking Therapeutics as a once-weekly subcutaneous injection and a once-daily oral tablet for chronic weight management. Neither formulation is approved, and no new drug application has been submitted. The company expects data from the subcutaneous phase 3 VANQUISH trials in the second half of 2027 and from the oral phase 3 SUNRISE trials in 2028, and has given no price.

Obesity affected 40.3% of U.S. adults in 2021 to 2023, and was associated with $1,861 in excess annual medical costs per adult in 2019 dollars. Approved incretin-based comparators for chronic weight management include semaglutide (injection and tablet), tirzepatide (injection), and orforglipron (tablet).

The evidence for the subcutaneous formulation comprises one peer-reviewed phase 2 trial (VENTURE, 176 participants, 13 weeks), in which placebo-adjusted weight change at week 13 ranged from −7.43 to −13.08 percentage points across doses of 2.5 to 15 mg, and phase 1 studies reported in press releases and posters, including a maintenance study of every-other-week and monthly dosing after 21 weeks of weekly induction. The evidence for the oral formulation comprises one phase 2 trial (VENTURE-Oral Dosing, 280 participants, 13 weeks) reported in a press release, a congress poster, and company presentations, with placebo-adjusted weight change of −1.0% to −10.9% at doses of 15 to 120 mg, treatment discontinuation of 20% to 38% across dose arms compared with 18% for placebo, and a 28-day phase 1 study. In both formulations, gastrointestinal adverse events were the most common adverse events and the most common reason for discontinuing treatment.

The phase 2 trials lasted 13 weeks, excluded people with diabetes, and reported no weight-loss plateau at week 13, so the effect after the 1 year of treatment that FDA draft guidance uses as its efficacy benchmark is not known for either formulation. The oral phase 3 doses (27.5, 35, and 55 mg) were not studied as fixed-dose arms in phase 2. Efficacy and safety at the phase 3 doses and durations, in people with type 2 diabetes, and against an active comparator have not been reported for either formulation.